{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:56:18Z","timestamp":1790283378933,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T00:00:00Z","timestamp":1547251200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1093\/jac\/dky558","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T07:10:28Z","timestamp":1544425828000},"page":"1425-1429","source":"Crossref","is-referenced-by-count":30,"title":["Use of ceftazidime\/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series"],"prefix":"10.1093","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-0083","authenticated-orcid":false,"given":"G","family":"Spoletini","sequence":"first","affiliation":[{"name":"The Leeds Regional Adult Cystic Fibrosis Centre, St James\u2019s University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK"},{"name":"Leeds Institute of Medical Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Etherington","sequence":"additional","affiliation":[{"name":"The Leeds Regional Adult Cystic Fibrosis Centre, St James\u2019s University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Shaw","sequence":"additional","affiliation":[{"name":"The Leeds Regional Adult Cystic Fibrosis Centre, St James\u2019s University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I J","family":"Clifton","sequence":"additional","affiliation":[{"name":"The Leeds Regional Adult Cystic Fibrosis Centre, St James\u2019s University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Denton","sequence":"additional","affiliation":[{"name":"The Leeds Regional Adult Cystic Fibrosis Centre, St James\u2019s University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK"},{"name":"Department of Microbiology, Leeds General Infirmary, Leeds Teaching Hospital NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Whitaker","sequence":"additional","affiliation":[{"name":"The Leeds Regional Adult Cystic Fibrosis Centre, St James\u2019s University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D G","family":"Peckham","sequence":"additional","affiliation":[{"name":"The Leeds Regional Adult Cystic Fibrosis Centre, St James\u2019s University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK"},{"name":"Leeds Institute of Medical Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"2019042309332643900_dky558-B1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"2019042309332643900_dky558-B2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcf.2004.01.005","article-title":"Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults","volume":"3","author":"Courtney","year":"2004","journal-title":"J Cyst Fibros"},{"key":"2019042309332643900_dky558-B3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1569-1993(02)00143-1","article-title":"Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis","volume":"2","author":"Mirakhur","year":"2003","journal-title":"J Cyst Fibros"},{"key":"2019042309332643900_dky558-B4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pupt.2018.04.007","article-title":"Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: real life experience of a large adult CF centre","volume":"50","author":"Spoletini","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"2019042309332643900_dky558-B5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CE.S40698","article-title":"Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections","volume":"9","author":"Lagac\u00e9-Wiens","year":"2014","journal-title":"Core Evid"},{"key":"2019042309332643900_dky558-B6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1128\/AAC.02161-13","article-title":"Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model","volume":"58","author":"Housman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309332643900_dky558-B7","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309332643900_dky558-B8","doi-asserted-by":"crossref","first-page":"e01858","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against \u03b2-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309332643900_dky558-B9","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2147\/IDR.S173804","article-title":"Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime\u2013avibactam","volume":"11","author":"Atkin","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2019042309332643900_dky558-B10","doi-asserted-by":"crossref","first-page":"e00590","DOI":"10.1128\/AAC.00590-18","article-title":"In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam","volume":"62","author":"Van Dalem","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309332643900_dky558-B11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","article-title":"Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients","volume":"3","author":"Papp-Wallace","year":"2017","journal-title":"ACS Infect Dis"},{"key":"2019042309332643900_dky558-B12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2019042309332643900_dky558-B13","doi-asserted-by":"crossref","first-page":"e02213-17.","DOI":"10.1128\/AAC.02213-17","article-title":"Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime-avibactam","volume":"62","author":"Tamma","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309332643900_dky558-B14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2018.07.010","article-title":"Evaluation of ceftazidime-avibactam for serious infections due to multidrug and extensive drug resistant Pseudomonas aeruginosa","volume":"15","author":"Rodr\u00edguez-N\u00fa\u00f1ez","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2019042309332643900_dky558-B15","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/jac\/dky124","article-title":"Efficacy and safety of ceftazidime\/avibactam: a systematic review and meta-analysis","volume":"73","author":"Sternbach","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019042309332643900_dky558-B16","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/jac\/dky204","article-title":"Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme","volume":"73","author":"Stone","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019042309332643900_dky558-B17","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/jac\/dky136","article-title":"Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime\/avibactam plus aztreonam","volume":"73","author":"Barlow","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019042309332643900_dky558-B18","doi-asserted-by":"crossref","first-page":"e00988","DOI":"10.1128\/AAC.00988-17","article-title":"Pharmacokinetic-pharmacodynamic target attainment analyses to determine optimal dosing of ceftazidime-avibactam for the treatment of acute pulmonary exacerbations in patients with cystic fibrosis","volume":"61","author":"Bensman","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309332643900_dky558-B19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/clinids\/23.3.532","article-title":"Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation","volume":"23","author":"Saiman","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2019042309332643900_dky558-B20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1378\/chest.123.5.1495","article-title":"Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis","volume":"123","author":"Smith","year":"2003","journal-title":"Chest"},{"key":"2019042309332643900_dky558-B21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkm481","article-title":"Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis","volume":"61","author":"Etherington","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2019042309332643900_dky558-B22","doi-asserted-by":"crossref","first-page":"e01379","DOI":"10.1128\/AAC.01379-18","article-title":"Mutation-driven evolution of Pseudomonas aeruginosa in the presence of either ceftazidime or ceftazidime-avibactam","volume":"62","author":"Sanz-Garc\u00eda","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/5\/1425\/28501242\/dky558.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T09:36:12Z","timestamp":1556012172000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/5\/1425\/5288573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,1,11]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky558","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,1,11]]}}}